Insights - Amarin Corporation (AMRN) reported quarterly results on Friday morning, $0.02 ahead of consensus EPS but below expectations on the top-line with a $1.6M miss. Cost-cutting … Continue Reading
Read nowInsights - Sarepta Therapeutics (SRPT) last Thursday morning released its fourth quarter and full-year 2013 financial results and hosted a conference call for investors. SRPT’s 2014 outlook … Continue Reading
Read nowInsights - Bristol-Myers Squibb (BMY) on Monday announced that the U.S. FDA granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation as a combination therapy … Continue Reading
Read nowInsights - Threshold Pharmaceuticals (THLD) announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company’s pivotal phase 3 … Continue Reading
Read nowInsights - Vertex Pharmaceuticals (VRTX) announced that Kalydeco, its drug for cystic fibrosis (CF), showed potential benefit in patients 18 or older, despite missing a phase 3 … Continue Reading
Read nowInsights - On the heels of dropping its bid to acquire troubled Transcept Pharmaceuticals (TSPT), Retrophin, Inc. (RTRX) announced its newest clinical development candidate on Wednesday: RE-034 … Continue Reading
Read nowInsights - Alcobra Ltd. (ADHD) announced on Monday that its proprietary non-stimulant drug candidate, Metadoxine ER (MG01CI), delivered statistically positive results in a phase 2b clinical trial in adults with … Continue Reading
Read now
